Sarepta Therapeutics, Inc. (SRPT) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 54 analysts43.4% Below Target
SRPT trades 43.4% below Wall Street's consensus target of $25.14.
Current Price$17.53
Average Target$25.14
Target
Current
Low$14.00
Median$25.00
High$35.00
Analyst Target Range
Forward P/E5.0x
(Value)
PEG Ratio—
Implied Growth+560.7%
(High Growth)
Analyst Spread83.5%
(Wide Disagreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes SRPT achieves its forward estimates and maintains a stable P/E multiple of 5.0x. This scenario reflects the blended consensus of 54 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
SRPT Price Target Analysis
Updated June 21, 2026As of June 21, 2026, Sarepta Therapeutics, Inc. (SRPT) has a Wall Street consensus price target of $25.14, based on estimates from 54 covering analysts. With the stock currently trading at $17.53, this represents a potential upside of +43.4%. The company has a market capitalization of $1.85B.
Analyst price targets range from a low of $14.00 to a high of $35.00, representing a 84% spread in expectations. The median target of $25.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 30 analysts rating the stock as a Buy or Strong Buy,18 rating it Hold, and 6 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, SRPT trades at a trailing P/E of -2.5x and forward P/E of 5.0x. Analysts expect EPS to grow +560.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+436.1%
Industry Consensus
Avg Forward P/E
33.4x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 BMRNBioMarin Pharmaceutical Inc. | $10.5B | $54.69 | $89.93 | +64.4% | Buy | 11.1x | 41 |
 ALNYAlnylam Pharmaceuticals, Inc. | $37.1B | $278.09 | $454.27 | +63.4% | Buy | 37.1x | 52 |
 RAREUltragenyx Pharmaceutical Inc. | $2.7B | $27.44 | $48.36 | +76.2% | Buy | — | 33 |
 IONSIonis Pharmaceuticals, Inc. | $12.2B | $74.12 | $109.44 | +47.7% | Buy | — | 32 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 KRYSKrystal Biotech, Inc. | $10.3B | $348.06 | $336.40 | -3.4% | Buy | 44.9x | 17 |
 CRSPCRISPR Therapeutics AG | $5.2B | $54.09 | $71.67 | +32.5% | Buy | — | 38 |
 EDITEditas Medicine, Inc. | $263M | $2.69 | $5.00 | +85.9% | Buy | — | 25 |
 NTLAIntellia Therapeutics, Inc. | $1.8B | $15.67 | $26.13 | +66.8% | Buy | — | 39 |
 SGMOSangamo Therapeutics, Inc. | $75M | $0.18 | $7.25 | +3927.8% | Hold | — | 14 |
SRPT — Frequently Asked Questions
Quick answers to the most common questions about buying SRPT stock.
What is the SRPT stock price target for 2026?
The consensus Wall Street price target for SRPT is $25.14, representing 43.4% upside from the current price of $17.53. With 54 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is SRPT a buy, sell, or hold?
SRPT has a consensus rating of "Buy" based on 54 Wall Street analysts. The rating breakdown is predominantly bullish, with 30 Buy/Strong Buy ratings. The consensus 12-month price target of $25.14 implies 43.4% upside from current levels.
Is SRPT stock overvalued or undervalued?
With a forward P/E of 4.9725x, SRPT trades at a relatively low valuation. The consensus target of $25.14 implies 43.4% appreciation, suggesting meaningful undervaluation.
How high can SRPT stock go?
The most bullish Wall Street analyst has a price target of $35 for SRPT, while the most conservative target is $14. The consensus of $25.14 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover SRPT stock?
SRPT is heavily covered by Wall Street, with 54 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 30 have Buy ratings, 18 recommend Hold, and 6 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the SRPT stock forecast?
The 12-month SRPT stock forecast based on 54 Wall Street analysts shows a consensus price target of $25.14, with estimates ranging from $14 (bear case) to $35 (bull case). The median consensus rating is "Buy".
What is SRPT's forward P/E ratio?
SRPT trades at a forward P/E ratio of 5.0x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy SRPT stock?
Wall Street analysts are very optimistic on SRPT, with a "Buy" consensus rating and $25.14 price target (43.4% upside). 30 of 54 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do SRPT price targets vary so much?
SRPT analyst price targets range from $14 to $35, a 84% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $25.14 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare